Endo International PLC (NASDAQ:ENDP) was upgraded by stock analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Friday.
Several other equities research analysts have also recently issued reports on ENDP. Vetr cut shares of Endo International PLC from a “strong-buy” rating to a “hold” rating and set a $11.34 price target on the stock. in a research note on Thursday, April 27th. BMO Capital Markets reaffirmed a “hold” rating and set a $15.00 price target on shares of Endo International PLC in a research note on Monday, May 1st. Canaccord Genuity set a $14.00 price target on shares of Endo International PLC and gave the stock a “hold” rating in a research note on Monday, May 1st. Zacks Investment Research raised shares of Endo International PLC from a “sell” rating to a “hold” rating in a research note on Tuesday, May 2nd. Finally, Mizuho reaffirmed a “buy” rating and set a $19.00 price target (up from $18.00) on shares of Endo International PLC in a research note on Thursday, May 25th. Three equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and five have given a buy rating to the company. Endo International PLC currently has a consensus rating of “Hold” and an average price target of $14.75.
Endo International PLC (NASDAQ:ENDP) traded up 0.9919% during trading on Friday, reaching $8.7156. 2,870,092 shares of the company were exchanged. The firm’s market capitalization is $1.95 billion. Endo International PLC has a 12 month low of $7.41 and a 12 month high of $24.93. The stock has a 50 day moving average price of $10.54 and a 200 day moving average price of $11.45.
Endo International PLC (NASDAQ:ENDP) last released its quarterly earnings results on Tuesday, August 8th. The company reported $0.93 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.74 by $0.19. Endo International PLC had a negative net margin of 126.93% and a positive return on equity of 37.58%. The company had revenue of $875.73 million for the quarter, compared to analysts’ expectations of $832.66 million. During the same period last year, the company earned $0.86 EPS. The firm’s revenue for the quarter was down 4.9% compared to the same quarter last year. On average, analysts expect that Endo International PLC will post $3.52 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “BidaskClub Upgrades Endo International PLC (ENDP) to “Sell”” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://sportsperspectives.com/2017/08/18/bidaskclub-upgrades-endo-international-plc-endp-to-sell.html.
In related news, CFO Blaise Coleman purchased 6,500 shares of the company’s stock in a transaction that occurred on Tuesday, August 15th. The stock was acquired at an average price of $7.89 per share, for a total transaction of $51,285.00. Following the completion of the purchase, the chief financial officer now owns 13,729 shares in the company, valued at $108,321.81. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Terrance J. Coughlin purchased 20,000 shares of the company’s stock in a transaction that occurred on Thursday, August 10th. The stock was bought at an average price of $7.70 per share, with a total value of $154,000.00. Following the purchase, the chief operating officer now owns 181,369 shares of the company’s stock, valued at approximately $1,396,541.30. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 36,000 shares of company stock valued at $279,460. Insiders own 0.50% of the company’s stock.
Several hedge funds have recently modified their holdings of ENDP. James Investment Research Inc. bought a new stake in shares of Endo International PLC during the second quarter worth about $113,000. Macquarie Group Ltd. raised its stake in shares of Endo International PLC by 132.1% in the fourth quarter. Macquarie Group Ltd. now owns 6,500 shares of the company’s stock worth $107,000 after buying an additional 3,700 shares during the period. OppenheimerFunds Inc. raised its stake in shares of Endo International PLC by 182.9% in the first quarter. OppenheimerFunds Inc. now owns 2,873,153 shares of the company’s stock worth $32,065,000 after buying an additional 1,857,678 shares during the period. Hartford Investment Management Co. bought a new stake in shares of Endo International PLC during the first quarter worth about $1,363,000. Finally, Ameriprise Financial Inc. raised its stake in shares of Endo International PLC by 685.0% in the first quarter. Ameriprise Financial Inc. now owns 554,138 shares of the company’s stock worth $6,185,000 after buying an additional 483,545 shares during the period. Institutional investors and hedge funds own 92.27% of the company’s stock.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.